Administration of FOLFIRINOX for Advanced Pancreatic Cancer: Physician Practice Patterns During Early Use

Advanced pancreatic cancer results in high morbidity and mortality. The standard of care treatment in the advanced setting changed in 2011 with the introduction of FOLFIRINOX (FFX) chemotherapy. However, it was highly toxic with significant risk of complications. We assessed the practice patterns of...

書目詳細資料
發表在:	Current Oncology
Main Authors:	Joanna Gotfrit, Horia Marginean, Yoo-Joung Ko, Akmal Ghafoor, Petr Kavan, Haji Chalchal, Shahid Ahmed, Karen Mulder, Patricia Tang, Rachel Goodwin
格式:	Article
語言:	英语
出版:	MDPI AG 2025-02-01
主題:	FOLFIRINOX advanced pancreatic cancer clinical practice practice patterns prescribing
在線閱讀:	https://www.mdpi.com/1718-7729/32/3/128

相似書籍

The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis
由: Beilei Zhang, et al.
出版: (2021-06-01)

Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients
由: Konstantin Schlick, et al.
出版: (2021-02-01)

Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient
由: Anne Katrin Berger, et al.
出版: (2017-12-01)

Three cachexia phenotypes and the impact of fat‐only loss on survival in FOLFIRINOX therapy for pancreatic cancer
由: Joshua K. Kays, et al.
出版: (2018-08-01)

Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX
由: Young Hoon Choi, et al.
出版: (2021-03-01)

FOLFIRINOX for advanced pancreatic adenocarcinoma in Brazil: a single-institution experience
由: José Mauricio Mota, et al.
出版: (2018-01-01)

Efficacy and Safety of Different Sequences for mFOLFIRINOX (or SOXIRI) and Gemcitabine Plus Albumin-Bound Paclitaxel in Unresectable Pancreatic Cancer
由: Huang S, et al.
出版: (2025-10-01)

Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel
由: Taro Shibuki, et al.
出版: (2024-07-01)

Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection
由: Adam R. Wolfe, et al.
出版: (2020-07-01)

Skeletal Muscle Index Changes on Locoregional Treatment Application After FOLFIRINOX and Survival in Pancreatic Cancer
由: Ji Hye Min, et al.
出版: (2025-02-01)

Global metabolomic profiling of tumor tissue and paired serum samples to identify biomarkers for response to neoadjuvant FOLFIRINOX treatment of human pancreatic cancer
由: Manoj Amrutkar, et al.
出版: (2025-02-01)

Second-line Modified GTX versus Gemcitabine-Nab-Paclitaxel (GmAb) Following First-Line FOLFIRINOX in Advanced Pancreatic Cancer: A Retrospective Analysis at the American University of Beirut Medical Center (AUBMC)
由: Sally Temraz, et al.
出版: (2023-10-01)

Development of transcriptomic tools for predicting the response to individual drug of the mFOLFIRINOX regimen in patients with metastatic pancreatic cancer
由: Nicolas Fraunhoffer, et al.
出版: (2024-09-01)

Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine-nab-paclitaxel in advanced pancreatic cancer
由: Lenka N.C. Boyd, et al.
出版: (2024-09-01)

Impact and optimal timing of local therapy addition in borderline resectable or locally advanced pancreatic cancer after FOLFIRINOX chemotherapy
由: Kangpyo Kim, et al.
出版: (2024-03-01)

Metastatic pancreatic cancer now in remission: a case report and literature review
由: Charles W. Shi, et al.
出版: (2025-01-01)

Macrophages reprogramming driven by cancer-associated fibroblasts under FOLFIRINOX treatment correlates with shorter survival in pancreatic cancer
由: Zainab Hussain, et al.
出版: (2024-01-01)

A liquid biomarker signature of inflammatory proteins accurately predicts early pancreatic cancer progression during FOLFIRINOX chemotherapy
由: Casper W.F. van Eijck, et al.
出版: (2024-03-01)

Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single Institution
由: Qi Quan, et al.
出版: (2020-12-01)

Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
由: Q. P. Janssen, et al.
出版: (2021-03-01)

Prediction of surgical resectability after FOLFIRINOX chemotherapy for borderline resectable and locally advanced pancreatic cancer (PeRFormanCe): a multicenter prospective trial - trial protocol
由: Luís Filipe Abreu de Carvalho, et al.
出版: (2025-05-01)

Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial
由: J. L. van Dam, et al.
出版: (2023-08-01)

<i>TYMS</i> 3′-UTR Polymorphism: A Novel Association with FOLFIRINOX-Induced Neurotoxicity in Pancreatic Cancer Patients
由: Marina Emelyanova, et al.
出版: (2021-12-01)

Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial
由: Christelle Bouchart, et al.
出版: (2023-09-01)

Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study
由: A. Gueiderikh, et al.
出版: (2024-02-01)

Pre-treatment inflamed tumor immune microenvironment is associated with FOLFIRINOX response in pancreatic cancer
由: Zachary Gao, et al.
出版: (2023-11-01)

COMBINATION CHEMOTHERAPY REGIMENS IN PANCREATIC CANCER
由: A. S. POPOVA, et al.
出版: (2017-06-01)

改良FOLFIRINOX方案一线治疗晚期转移性胰腺癌
由: 农天文, et al.
出版: (2018-01-01)

Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
由: Quisette P. Janssen, et al.
出版: (2020-01-01)

A resected case of acinar cell carcinoma of the pancreas with liver metastasis following chemotherapy using modified FOLFIRINOX
由: Shuhei Yamada, et al.
出版: (2023-08-01)

Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study)
由: Elisa Giommoni, et al.
出版: (2021-05-01)

Comparison of different Pancreatic cancer treatments: a three-year retrospective study in the oncology center of Tangier university hospital, Morocco
由: Houda Abrini, et al.
出版: (2023-12-01)

miRNA signatures underlie chemoresistance in the gemcitabine-resistant pancreatic ductal adenocarcinoma cell line MIA PaCa-2 GR
由: Ryan N. Fuller, et al.
出版: (2024-06-01)

[Comment] Brazil-TNT : a randomized phase 2 trial of neoadjuvant chemoradiation followed by FOLFIRINOX versus chemoradiation for stage Ⅱ/Ⅲ rectal cancer
由: Li Laiyuan, et al.
出版: (2024-08-01)

Predictive factors for survival in borderline resectable and locally advanced pancreatic cancer: are these really two different entities?
由: Luís Filipe Abreu de Carvalho, et al.
出版: (2023-09-01)

Integrated Analysis of the RASH Study with the Use of the “Burden of Therapy” (BOTh<sup>®TM</sup>) Methodology—A Novel Tool for Assessing Adverse Events in Metastatic Pancreatic Cancer
由: Klara Dorman, et al.
出版: (2023-06-01)

Conversion Surgery for Pancreatic Cancer—The Impact of Neoadjuvant Treatment
由: Ulla Klaiber, et al.
出版: (2020-01-01)

Survival benefits of adjuvant chemotherapy after conversion surgery in patients with advanced pancreatic cancer
由: Yoon Suk Lee, et al.
出版: (2025-01-01)

Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights
由: Ashish Manne, et al.
出版: (2025-04-01)

Cost-effectiveness analysis of first-line combination chemotherapy regimens for metastatic pancreatic cancer and evidence-based pricing strategy of liposomal irinotecan in China
由: Zuojuan Xiang, et al.
出版: (2024-12-01)